insulin sensitization

GQ-16 is a partial agonist of PPARγ with a Ki of 160 nM. GQ-16 reduces adipogenic actions and promotes insulin Sensitization without weight gain.

Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.

JBSNF-000028 belongs to small molecule inhibitors, serving as a nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=33 nM (human), 190 nM (monkey), 210 nM (mouse)), with oral activity and cell permeability, for research on metabolic disorders, possessing insulin-sensitizing, glucose-lowering, and weight-reducing effects.

S-15261 is a potent oral antihyperglycemic agent that reduces hepatic glucose production through direct action and insulin sensitization. S-15261 is applicable for research on insulin resistance syndrome.

Morolic acid and moronic acid have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1. Moro

Moronic acid shows oral therapeutic efficacy in HSV-infected mice and possessed novel anti-HSV activity. It also shows significant anti-HIV activity (EC(50) 186) and was modified to develop more potent anti-AIDS agents. Moronic acid is a new structural lead for anti-EBV drug development, can substantially reduce the numbers of EBV particles produced by the cells after lytic induction. Morolic and moronic acids have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1 as indicated by in vitro.